Before it gives a decision to ViroPharma's supplemental biologics license application, the Food and Drug Administration has asked the company to conduct an additional clinical study of its experimental angiodema drug Cinryze - the FDA told ViroPharma on Thursday that the placebo-controlled study submitted to support the application "lacked robustness."